Board of Trustees
John “Jack” R. Fowle III PhD, DABT
Rob de Vries, PhD
James J. Freeman, PhD, DABT
Thomas Hartung, MD, PhD
Nancy Beck, PhD, DABT
Dr. Beck is a toxicologist with fifteen years of applied public health experience. She brings to EBTC a broad policy perspective, deep understanding of US regulatory process, as well as detailed technical expertise and an ability to bring a scientific dialogue to the policy discussion to inform critical decision making. Dr. Beck is skilled in leading and directing interagency negotiations to improve policy, as well as establishing successful collaborations and partnerships with senior staff and policy officials throughout the Executive Office of the President and federal agencies.
Gerry Kenna, PhD
Dr. Kenna is Pharmaceutical Director of the Safer Medicines Trust, which is an independent UK charity. In this role, he is focused on developing and gaining regulatory acceptance of human biology-based methods that can improve human safety assessment of drugs and other chemicals. In addition, he is an independent Drug Safety Consultant who advises clients in pharmaceutical and biotech companies on how best to select and develop efficacious and safe new drugs, and to validate new predictive safety methods and strategies. Previously, he held scientific leadership roles as a toxicologist in the pharmaceutical and agrochemical industries (at AstraZeneca, Syngenta and Zeneca). These were preceded by academic faculty positions (at Imperial College School of Medicine, London UK; National Institutes of Health, MD USA; King’s College Hospital Medical School, London UK and the National Institute for Medical Research, London UK), in which he led research teams that explored mechanisms underlying human adverse drug reactions. He has authored or co-authored >100 peer reviewed scientific publications, is a member of the International Society for the Study of Xenobiotics and a Fellow of the British Toxicology Society. He received a BSc Hons in Biochemistry from the University of Leeds UK and a PhD in Biochemistry from the University of London UK.
Andrew A. Rooney, PhD
Dr Rooney is the Deputy Director, Office of Health Assessment and Translation (OHAT) in the Division at the National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS). He has 20 years of experience in toxicology and risk assessment for the protection of public health resulting in contributions to the peer-reviewed literature, government assessments (NTP Monographs, EPA IRIS Toxicological Reviews), and book chapters. He has been actively involved in developing risk assessment methods and guidance throughout his professional career, and is a principal author of the 2012 WHO/IPCS Guidance for Immunotoxicity Risk Assessment for Chemicals. Most recently, Dr Rooney has been working on emerging issues in toxicology and environmental health, including methods to address study quality in terms of risk of bias for human, animal, and mechanistic studies, and adaptation of systematic review methods for addressing environmental health questions. He led the team that developed the OHAT Approach to Systematic Review and Evidence Integration. Dr. Rooney has an MS and PhD in zoology from the University of Florida.
Emily S Sena, PhD
Dr Sena is a Research Fellow at the Centre for Clinical Brain Sciences, University of Edinburgh, Convener, CAMARADES. She has a background in neuroscience and is a research fellow specialised in the validity of preclinical studies. Her research interests are in the use of systematic review and meta-analysis of preclinical efficacy studies to increase the understanding of critical facets of translational medicine and developing new hypotheses for testing in the laboratory. Since 2015 Dr Sena has led the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES), a multicentre international research collaboration facilitating the pooling and analysis of data from a range of disease models across the basic sciences. To support this she has developed an internationally accessible database, similar to the Cochrane library, to facilitate interpretation of the preclinical data used to justify progression to clinical trial. Dr Sena's research has informed laboratory practice guidelines, editorial policy and the design of clinical trial protocols.
Didier Verloo, PhD
Didier Verloo is working for the European Food Safety Authority (EFSA) since 2005 where he is heading the Assessment and Methodological Support Unit since 2008. This multidisciplinary unit leads and supports the development, implementation and review of evidence based risk assessment and decision support approaches in all fields within EFSA’s remit and was responsible for the EFSA guidance on Systematic Review in food and feed safety risk assessment and the EFSA guidance on Expert Knowledge Elicitations. Recently the unit developed and started to implement an overall framework for Promoting Methods for Evidence Use in Scientific assessments (Prometheus).
Didier Verloo graduated as a Veterinarian in 1995 and started his professional career at the Institute of Tropical Medicine in Antwerp on the development of diagnostics, interpretation and medical decision making based on diagnostic test results in human and animal trypanosomosis (sleeping sickness) and worked from 2000-2005 for the Belgian government as an epidemiologist and Risk Assessor. Over those years he built up academic and hands on experience in biostatistics, epidemiology, risk analysis, test validation and provided risk analysis consultancy in public health, construction, finance and engineering.
The EBTC staff members Drs. Katya Tsaioun, Martin L. Stephens, and Sebastian Hoffmann are non-voting members of the Board of Trustees.